An assessment of the supply, programmatic use, and regulatory issues of single low-dose primaquine as a Plasmodium falciparum gametocytocide for sub-Saharan Africa

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Chen, Ingrid ^a   Poirot, Eugenie ^a   Newman, Mark ^b   Kandula, Deepika ^b   Shah, Renee ^b   Hwang, Jimee ^a,c   Cohen, Justin M ^b   Gosling, Roly ^a   Rooney, Luke ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CLINTON HEALTH ACCESS INITIATIVE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

8 aminoquinoline; Africa; Drug dosing; Drug manufacturing; Drug production; Drug regulation; G6PD; Glucose 6 phosphate dehydrogenase deficiency; Malaria transmission; Plasmodium falciparum; Primaquine

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PRIMAQUINE; TUBERCULOSTATIC AGENT; ANTIMALARIAL AGENT;

ARTICLE; COMORBIDITY; DRUG CONTROL; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG POTENTIATION; DRUG QUALITY; DRUG SAFETY; DRUG USE; ETHIOPIA; GAMETOCYTE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEALTH CARE DISPARITY; HEALTH CARE DISTRIBUTION; HEALTH CARE NEED; HUMAN; MALARIA CONTROL; MALARIA FALCIPARUM; NONHUMAN; PLASMODIUM FALCIPARUM; PREVENTIVE MEDICINE; RECOMMENDED DRUG DOSE; SEMI STRUCTURED INTERVIEW; SENEGAL; SINGLE DRUG DOSE; SWAZILAND; TANZANIA; VIRAL CLEARANCE; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; ZAMBIA; AFRICA SOUTH OF THE SAHARA; ATTITUDE TO HEALTH; DRUG EFFECTS; DRUG INTERACTION; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HEALTH CARE POLICY; LEGISLATION AND JURISPRUDENCE; MALARIA, FALCIPARUM; QUESTIONNAIRE; SUPPLY AND DISTRIBUTION;

AFRICA SOUTH OF THE SAHARA; ANTIMALARIALS; DRUG INTERACTIONS; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH POLICY; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PRIMAQUINE; SURVEYS AND QUESTIONNAIRES;

EID: 84934998246     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0714-3     Document Type: Article

References (27)

1. WHO. World Malaria Report 2014. World Health Organization, Geneva
2. White NJ, Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malar J. 2012;11:418.
3. Vale N, Moriera R, Gomes P. Primaquine revisited six years after its discovery. Eur J Med Chem. 2009;44:937-53.
4. Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, Hwang J, et al. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet. 2013;382:900-11.
5. White NJ. Primaquine to prevent transmission of falciparum malaria. Lancet. 2013;13:175-81.
6. WHO and Global Malaria Programme: Updated WHO Policy Recommendation (October 2012). Single dose Primaquine as a gametocytocide in Plasmodium falciparum malaria. [ http://www.who.int/malaria/pq-updated-policy-recommendation-en-102012.pdf ]
7. Chen IT, Gosling R. Targeting Plasmodium falciparum with primaquine: same efficacy, improved safety with a lower dose? Expert Rev Clin Pharm. 2014;7:681-6.
8. Eziefula AC, Gosling R, Hwang J, Hsiang MS, Bousema T, von Seidlein L, et al. Rationale for short course primaquine in Africa to interrupt malaria transmission. Malar J. 2012;11:360.
9. Newman M, Rooney L, Kandula D, Shah R, Hwang J, Cohen J, et al. Implementation of Low Dose Primaquine as a Gametocytocide in sub-Saharan Africa. 2013. http://globalhealthsciences.ucsf.edu/sites/default/files/content/ghg/mei-primaquine-report.pdf.
10. Guideline on Submission of Documentation for Prequalification of Multisource (generic) Finished Pharmaceutical Products (FPPs) approved by Stringent Regulatory Authorities (SRAs) [ http://apps.who.int/prequal/info-applicants/Guidelines/PQProcGenericSRA-July2011.pdf ]
11. Drug Master Files (DMFs) [ http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/DrugMasterFilesDMFs/UCM2007046#dmffiles ]
12. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77-101.
13. Hayes DJ, Buuren S, ter Kuile F, Stasinopoulos DM, Rigby RA, Terlouw A. Developing regional weight-for-age growth references for malaria-endemic countries to optimize age-based dosing of antimalarials. Bull World Health Organ. 2015;93:74-83.
14. Nair A, Abrahamsson B, Barends DM, Groot DW, Kopp S, Polli JE, et al. Biowaiver monographs for immediate-release solid oral dosage forms: primaquine phosphate. J Pharm Sci. 2012;101:936-45.
15. Single Low-dose Primaquine to Interrupt P. falciparum Transmission in Africa: A Roadmap Update. Meeting Summary. [ http://globalhealthsciences.ucsf.edu/sites/default/files/content/ghg/mei-london-pq-summary.pdf ]
16. Global Report. UNAIDS report on the global AIDS epidemic 2013. [ http://www.unaids.org/sites/default/files/media-asset/UNAIDS-Global-Report-2013-en-1.pdf ]
17. Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med. 2004;116(Suppl 7A):27S-43.
18. Poirot E, Skarbinski J, Sinclair D, Kachur SP, Slutsker L, Hwang J. Mass drug administration for malaria. Cochrane Database Syst Rev. 2013;12:CD008846.
19. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9:e1001339.
20. von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, et al. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J. 2013;12:112.
21. Beutler E, Yeh M, Fairbanks VF. The normal human female as a mosaic of X-chromosome activity: studies using the gene for G-6-PD-deficiency as a marker. Proc Natl Acad Sci U S A. 1962;48:9-16.
22. World Health Organization Invitations for Expressions of Interest (EOIs) [ http://apps.who.int/prequal/info-applicants/info-for-applicants-EOIs.htm ]
23. Tiono AB, Ouédraogo A, Ogutu B, Diarra A, Coulibaly S, Gansané A, et al. A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso. Malar J. 2013;12:79.
24. Cook J, Xu W, Msellem M, Vonk M, Bergström B, Gosling R, et al. Mass screening and treatment on the basis of results of a Plasmodium falciparum-specific rapid diagnostic test did not reduce malaria incidence in Zanzibar. J Infect Dis. 2014;pii: jiu655. [Epub ahead of print]
25. Mosha JF, Sturrock HJ, Greenhouse B, Greenwood B, Sutherland CJ, Gadalla N, et al. Epidemiology of subpatent Plasmodium falciparum infection: implications for detection of hotspots with imperfect diagnostics. Malar J. 2013;12:221.
26. Maude RJ, Socheat D, Nguon C, Saroth P, Dara P, Li G, et al. Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance. PLoS One. 2012;7:e37166.
27. Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13:418.